{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:01:44Z","timestamp":1753876904283,"version":"3.41.2"},"reference-count":30,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T00:00:00Z","timestamp":1605139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>STUDY QUESTION<\/jats:title>\n                  <jats:p>Does progestin have an effect on heparanase level and procoagulant activity?<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>SUMMARY ANSWER<\/jats:title>\n                  <jats:p>Progestin increases the heparanase level and procoagulant activity via the estrogen receptor and the magnitude of the effect depends on the progestin type.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>WHAT IS KNOWN ALREADY<\/jats:title>\n                  <jats:p>Users of combined oral contraceptives (COCs) containing third- and fourth-generation progestins have a higher risk of venous thrombosis compared to those employing second-generation progestins. Heparanase protein is capable of degrading heparan sulfate (HS) chains and enhancing activation of the coagulation system. We have previously demonstrated that estrogen enhances the expression and procoagulant activity of heparanase.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>STUDY DESIGN, SIZE, DURATION<\/jats:title>\n                  <jats:p>Estrogen and progestin receptor positive breast carcinoma cell lines: EMT6, T47D and MCF-7 were compared to the MDA-231 breast carcinoma cell line devoid of these receptors. This observational study incorporated 45 users of third-generation COCs progestins, 21 users of fourth-generation COCs progestins and 28 individuals not using hormonal therapy and not pregnant per history.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>PARTICIPANTS\/MATERIALS, SETTING, METHODS<\/jats:title>\n                  <jats:p>Second-generation progestin\u2014levonorgestrel, third-generation progestin\u2014desogastrel (DSG), an estrogen receptor antagonist\u2014ICI 182.780 and a progestin receptor antagonist\u2014mifepristone, were added to cell lines. Heparanase level and procoagulant activity, HS levels, tissue factor (TF) activity and factor Xa levels were evaluated in the plasma of the study group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>MAIN RESULTS AND THE ROLE OF CHANCE<\/jats:title>\n                  <jats:p>Levonorgestrel and DSG increased heparanase levels in the cells and medium. The effect of DSG was more prominent and additive to that of estrogen. The effect was inhibited by ICI 182.780. In the plasma of COC users, heparanase procoagulant activity, HS levels, TF activity and factor Xa levels were significantly higher compared to controls. In COC pills containing the same dose of estrogen, the procoagulant effect of drospirenone was significantly stronger than that of DSG and gestodene.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>LIMITATIONS, REASONS FOR CAUTION<\/jats:title>\n                  <jats:p>The limitations of the study include a small number of participants in each study group, although the results are statistically significant and evaluated by several different coagulation parameters.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>WIDER IMPLICATIONS OF THE FINDINGS<\/jats:title>\n                  <jats:p>The study demonstrates a new mechanism through which progestin affects coagulation system activation and shows that this effect is progestin type-dependent. Development of a progestin derivative with an attenuated effect on heparanase procoagulant activity may reduce thrombotic risk.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>STUDY FUNDING\/COMPETING INTEREST(S)<\/jats:title>\n                  <jats:p>No external funding was sought for this study. Y.N. is named in a European patent application No. IL201200027 filed on 18 January 2012. Other authors have no conflict of interest to declare.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>TRIAL REGISTRATION NUMBER<\/jats:title>\n                  <jats:p>N\/A.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/humrep\/deaa263","type":"journal-article","created":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T19:12:42Z","timestamp":1601061162000},"source":"Crossref","is-referenced-by-count":1,"title":["Progestin type affects the increase of heparanase level and procoagulant activity mediated by the estrogen receptor"],"prefix":"10.1093","author":[{"given":"Sharon","family":"Treger","sequence":"first","affiliation":[{"name":"Thrombosis and Hemostasis Unit, Rambam Health Care Campus, Haifa, Israel"},{"name":"The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanny","family":"Ackerman","sequence":"additional","affiliation":[{"name":"Thrombosis and Hemostasis Unit, Rambam Health Care Campus, Haifa, Israel"},{"name":"The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Kaplan","sequence":"additional","affiliation":[{"name":"Thrombosis and Hemostasis Unit, Rambam Health Care Campus, Haifa, Israel"},{"name":"The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shourouk","family":"Ghanem","sequence":"additional","affiliation":[{"name":"Thrombosis and Hemostasis Unit, Rambam Health Care Campus, Haifa, Israel"},{"name":"The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yona","family":"Nadir","sequence":"additional","affiliation":[{"name":"Thrombosis and Hemostasis Unit, Rambam Health Care Campus, Haifa, Israel"},{"name":"The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,11,12]]},"reference":[{"key":"2020121110195802500_deaa263-B1","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1093\/humrep\/det092","article-title":"Endogenous thrombin potential is higher during the luteal phase than during the follicular phase of a normal menstrual cycle","volume":"28","author":"Chaireti","year":"2013","journal-title":"Hum Reprod"},{"key":"2020121110195802500_deaa263-B2","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/ijgo.12455","article-title":"A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception","volume":"141","author":"Dragoman","year":"2018","journal-title":"Int J Gynecol Obstet"},{"key":"2020121110195802500_deaa263-B3","first-page":"8821","article-title":"Regulation of heparanase gene expression by estrogen in breast cancer","volume":"63","author":"Elkin","year":"2003","journal-title":"Cancer Res"},{"key":"2020121110195802500_deaa263-B4","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1042\/bj3301341","article-title":"Human platelet heparanase: purification, characterization and catalytic activity","volume":"330","author":"Freeman","year":"1998","journal-title":"Biochem J"},{"key":"2020121110195802500_deaa263-B5","doi-asserted-by":"crossref","first-page":"E1319","DOI":"10.1503\/cmaj.110463","article-title":"Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study","volume":"183","author":"Gronich","year":"2011","journal-title":"CMAJ"},{"key":"2020121110195802500_deaa263-B6","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1136\/bmj.2.5599.193","article-title":"Investigation of deaths from pulmonary, coronary, and cerebral thrombosis and embolism in women of child-bearing age","volume":"2","author":"Inman","year":"1968","journal-title":"Br Med J"},{"key":"2020121110195802500_deaa263-B7","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1210\/jc.2004-0857","article-title":"Progestin increases tissue factor gene expression, procoagulant activity, and invasion in the breast cancer cell line ZR-75-1","volume":"90","author":"Kato","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2020121110195802500_deaa263-B8","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0010-7824(01)00307-9","article-title":"Oral contraceptives and venous thromboembolism: a five-year national case-control study","volume":"65","author":"Lidegaard","year":"2002","journal-title":"Contraception"},{"key":"2020121110195802500_deaa263-B9","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1093\/humrep\/det257","article-title":"Heparanase procoagulant activity is elevated in women using oral contraceptives","volume":"28","author":"Matan","year":"2013","journal-title":"Hum Reprod"},{"key":"2020121110195802500_deaa263-B10","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.3324\/haematol.2010.023713","article-title":"Heparanase enhances the generation of activated factor X in the presence of tissue factor and activated factor VII","volume":"95","author":"Nadir","year":"2010","journal-title":"Haematologica"},{"key":"2020121110195802500_deaa263-B11","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1055\/s-0037-1608919","article-title":"Heparanase induces tissue factor pathway inhibitor expression and extracellular accumulation in endothelial and tumor cells","volume":"99","author":"Nadir","year":"2008","journal-title":"Thromb Haemost"},{"key":"2020121110195802500_deaa263-B12","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1111\/j.1538-7836.2006.02212.x","article-title":"Heparanase induces tissue factor expression in vascular endothelial and cancer cells","volume":"4","author":"Nadir","year":"2006","journal-title":"J Thromb Haemost"},{"key":"2020121110195802500_deaa263-B13","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1016\/j.thromres.2011.03.008","article-title":"An assay to evaluate heparanase procoagulant activity","volume":"128","author":"Nadir","year":"2011","journal-title":"Thromb Res"},{"key":"2020121110195802500_deaa263-B14","first-page":"M99","article-title":"Heparanase: a key enzyme involved in cell invasion","volume":"1471","author":"Parish","year":"2001","journal-title":"Biochim Biophys Acta"},{"key":"2020121110195802500_deaa263-B15","doi-asserted-by":"crossref","first-page":"18770","DOI":"10.1074\/jbc.273.30.18770","article-title":"Substrate specificity of heparanases from human hepatoma and platelets","volume":"273","author":"Pikas","year":"1998","journal-title":"J Biol Chem"},{"key":"2020121110195802500_deaa263-B16","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1160\/TH12-10-0771","article-title":"The effect of different hormonal contraceptives on plasma levels of free protein S and free TFPI","volume":"109","author":"Raps","year":"2013","journal-title":"Thromb Haemost"},{"key":"2020121110195802500_deaa263-B17","doi-asserted-by":"crossref","first-page":"5441","DOI":"10.2147\/OTT.S169947","article-title":"Mifepristone inhibits proliferation, migration and invasion of HUUA cells and promotes its apoptosis by regulation of FAK and PI3K\/AKT signaling pathway","volume":"11","author":"Sang","year":"2018","journal-title":"Onco Targets Ther"},{"key":"2020121110195802500_deaa263-B18","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/oxfordjournals.aje.a121082","article-title":"Thromboembolism and oral contraceptives: an epidemiologic case-control study","volume":"90","author":"Sartwell","year":"1969","journal-title":"Am J Epidemiol"},{"key":"2020121110195802500_deaa263-B19","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.bbrc.2006.01.048","article-title":"An ELISA method for the detection and quantification of human heparanase","volume":"341","author":"Shafat","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"2020121110195802500_deaa263-B20","doi-asserted-by":"crossref","first-page":"f5298","DOI":"10.1136\/bmj.f5298","article-title":"Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis","volume":"347","author":"Stegeman","year":"2013","journal-title":"BMJ"},{"key":"2020121110195802500_deaa263-B21","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/oxfordjournals.aje.a112148","article-title":"Thrombosis with low-estrogen oral contraceptives","volume":"102","author":"Stolley","year":"1975","journal-title":"Am J Epidemiol"},{"key":"2020121110195802500_deaa263-B22","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1017\/S1431927617000484","article-title":"Effect of progestin and synthetic progestins on whole blood clot formation and erythrocyte structure","volume":"23","author":"Swanepoel","year":"2017","journal-title":"Microsc Microanal"},{"key":"2020121110195802500_deaa263-B23","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/oxfordjournals.bmb.a072592","article-title":"Combined oral contraceptives: risks and benefits","volume":"49","author":"Thorogood","year":"1993","journal-title":"Br Med Bull"},{"key":"2020121110195802500_deaa263-B24","doi-asserted-by":"crossref","first-page":"b2921","DOI":"10.1136\/bmj.b2921","article-title":"The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study","volume":"339","author":"van Hylckama Vlieg","year":"2009","journal-title":"BMJ"},{"key":"2020121110195802500_deaa263-B25","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1538-7836.2008.02863.x","article-title":"Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor","volume":"6","author":"van Vliet","year":"2008","journal-title":"J Thromb Haemost"},{"key":"2020121110195802500_deaa263-B26","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1136\/bmj.2.5658.651","article-title":"Investigation of relation between use of oral contraceptives and thromboembolic disease. A further report","volume":"2","author":"Vessey","year":"1969","journal-title":"Br Med J"},{"key":"2020121110195802500_deaa263-B27","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1172\/JCI13662","article-title":"Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis","volume":"108","author":"Vlodavsky","year":"2001","journal-title":"J Clin Invest"},{"key":"2020121110195802500_deaa263-B28","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/1471-0528.12210","article-title":"Drospirenone-containing oral contraceptive pills and the risk of venous and arterial thrombosis: a systematic review","volume":"120","author":"Wu","year":"2013","journal-title":"BJOG"},{"key":"2020121110195802500_deaa263-B29","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1096\/fj.06-6840com","article-title":"Progestins overcome inhibition of platelet aggregation by endothelial cells by down-regulating endothelial NO synthase via glucocorticoid receptors","volume":"21","author":"Zerr-Fouineau","year":"2007","journal-title":"FASEB J"},{"key":"2020121110195802500_deaa263-B30","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1242\/jcs.01068","article-title":"Processing and activation of latent heparanase occurs in lysosomes","volume":"117","author":"Zetser","year":"2004","journal-title":"J Cell Sci"}],"container-title":["Human Reproduction"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/humrep\/advance-article-pdf\/doi\/10.1093\/humrep\/deaa263\/34862159\/deaa263.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/humrep\/advance-article-pdf\/doi\/10.1093\/humrep\/deaa263\/34862159\/deaa263.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,12]],"date-time":"2020-12-12T07:13:32Z","timestamp":1607757212000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/humrep\/advance-article\/doi\/10.1093\/humrep\/deaa263\/6030955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,12]]},"references-count":30,"URL":"https:\/\/doi.org\/10.1093\/humrep\/deaa263","relation":{},"ISSN":["0268-1161","1460-2350"],"issn-type":[{"type":"print","value":"0268-1161"},{"type":"electronic","value":"1460-2350"}],"subject":[],"published":{"date-parts":[[2020,11,12]]},"article-number":"deaa263"}}